Elevating Levels of Endogenous Circulating von Willebrand Factor (VWF): The Potential of HMB-002 as a Prophylactic Treatment of Von Willebrand Disease (VWD)

Henrik Ostergaard*[1], Minka Zivkovic[2], Prafull S. Gandhi[1], Caroline Rasmussen[1], Rane A. Harrison[1], Emil Poulsen[1], Dana Huskens[3], Mark Roest[3], Anais Naretto[4], Lars Holten-Andersen[1], Catherine J. Rea[1], Benny Sorensen[1], Rolf T. Urbanus[2], Mattias Häger[1]

[1]Hemab Therapeutics, [2]University Medical Center Utrecht, Utrecht, Netherlands, [3]Synapse Research Institute, Maastricht, Netherlands, [4]SARomics Biostructures, Lund, Sweden

EAHAD 2025 ▪ 18th Annual Congress of the European Association of Haemophilia and Allied Disorders ▪ Milan, Italy ▪ February 4-7, 2025

Disclosures for Henrik Ostergaard

In compliance with COI policy, EAHAD requires the following disclosures to the session audience:

Shareholder	Hemab Therapeutics
Grant / Research Support	No relevant conflicts of interest to declare
Consultant	No relevant conflicts of interest to declare
Employee	Hemab Therapeutics
Paid Instructor	No relevant conflicts of interest to declare
Speaker bureau	No relevant conflicts of interest to declare
Other	No relevant conflicts of interest to declare

Presentation includes discussion of the following off-label use of a drug or medical device:
N/A

Von Willebrand Disease – A Bleeding Disorder with Unmet Needs



Healthy – sufficient VWF



VWD – insufficient VWF



von Willebrand Factor (VWF)

- Multifunctional protein supporting
- **primary hemostasis** by mediating platelet adhesion and aggregation at sites of vascular injury by binding exposed collagen and platelet receptors
- **secondary hemostasis** by protecting FVIII in circulation

Von Willebrand Disease (VWD)

- Most common inherited bleeding disorder
- Results from **quantitative deficiency (0-50%) or defect in VWF**
- Broad spectrum of frequent bleeding events including heavy menstrual bleeding, often leading to iron deficiency

HMB-002 Aims to Directly Impact the Underlying Patho-etiology of VWD by Increasing Levels of VWF and FVIII

Functions of HMB-002

Binds & Accumulates VWF

- *Accumulates VWF*
  HMB-002 engages the FcRn pathway to protect VWF from degradation
- *Increases FVIII levels*
  Elevated VWF levels drive additional accumulation of FVIII

Restores Hemostasis in VWD

- *Primary Hemostasis*
  Elevated VWF levels enhance platelet recruitment to site of injury
- *Secondary Hemostasis*
  Accumulated FVIII further supports clot formation by contributing to secondary hemostasis



HMB-002 aims to offer subcutaneous, infrequent prophylactic treatment of people with VWD

Other studies applying a target accumulation strategy: Gandhi (2024) Nat Cardiovasc Res. 3(2):166–185 / McCluskey (2024) Haematologica. doi: 10.3324/haematol.2024.286076

HMB-002 Designed to Bind the C-terminal CK Domain of VWF



Targeting the C-terminal CK domain in VWF



Monovalent (one-arm) human antibody format



Human IgG4 + Fc effector silencing

- Significantly reduced Fcγ receptor binding compared to standard IgG4
- No cytokine release, platelet or completement activation in *ex vivo* studies**

*de Jong (2017) Thrombosis Research, 159:65; **abstract submitted to ISTH 2025 (Washington DC).

HMB-002 Selectively Binds to Epitope in the VWF CK Domain

Complex	Resolution
HMB-002 Fab : VWF CK	2.5 Å



No off-targets identified in screen of 6,500 human proteins using the Retrogenix® Cell Microarray Technology

Molecular model of full-length HMB-002 bound to the VWF C6-CK fragment*



K_D for HMB-002 binding at pH 7.4 and 25°C (SPR)	VWF CK	Plasma-derived VWF
	0.6 nM	0.1 nM

*Chen (2022) J Struct Biol, 214:107923 / Zhou (2014) Blood, 123:1785 / Scapin (2015) Nat Struct Mol Biol, 22:953

VWF Retains Key Functions in Presence of HMB-002

1 FVIII:VWF binding



2 VWF:RCo activity



VWF:GP1b binding (ELISA)



5 Whole-blood platelet capture on collagen surface at high shear





3 ADAMTS13 processing (plasma)



4 VWF:CBA



VWF:Collagen III binding (ELISA)



Methods

FVIII:VWF binding	Asserachrom® VWF:FVIIIB
VWF:RCo activity	STA®-VWF:RCo assay in citrated human plasma
VWF:GPIb binding	ELISA with immuno-captured GPIb ectodomain and ristocetin
ADAMTS13 processing	Citrated human plasma with ristocetin (2-h incubation)
VWF:CBA	ZYMUTEST™ VWF:CBA (collagen I/III)
VWF:Collagen ELISA	ELISA with coated human collagen III
Platelet capture at high shear	Microfluidic assay with citrated human whole blood and coated collagen I/III. Platelet capture recorded for 10 min at shear of 1000 s^{-1}

HMB-002 Accumulates Endogenous VWF and FVIII in Non-Human Primates

Prolonged VWF accumulation with retained multimer pattern after single-dose of HMB-002



VWF accumulation



VWF multimer distribution



Assays

- VWF:Ag using ELISA and human plasma calibrator
- VWF:RCo using STA®-VWF:RCo (Stago) and human plasma calibrator
- FVIII:Ag using Asserachrom® FVIII:Ag (Stago) and human plasma calibrator
- VWF multimer by gel electrophoresis and immunostaining (Hydrasys)

Observations across NHP studies[1] - FVIII Accumulates together with VWF

VWF accumulation vs gender



VWF:Ag at all timepoints ≥ day 8 (i.e., at full accumulation) across NHP studies

VWF:RCo follows VWF:Ag



FVIII follows VWF



[1] available data from PK, DRF, and 4w tox studies

Conclusion & Acknowledgement

HMB-002

Monovalent (one-arm) human antibody designed to bind and accumulate endogenous circulating VWF

In vitro and *in vivo* studies demonstrate

- Selective binding of HMB-002 to the C-terminal CK domain of VWF
- Key VWF functions retained when bound to HMB-002
- Accumulation of endogenous VWF and FVIII to about 2-fold of pre-dose level in cynomolgus monkey

Thank you to Hemab Therapeutics (Prafull S. Gandhi, Caroline Rasmussen, Rane A. Harrison, Emil Poulsen, Lars Holten-Andersen, Catherine J. Rea, Benny Sorensen, Mattias Häger), **UMC Utrecht** (Minka Zivkovic, Rolf T. Urbanus), **Synapse Research Institute** (Dana Huskens, Mark Roest), and **SARomics Biostructures** (Anais Naretto)

Sponsor: Hemab Therapeutics

NOW ENROLLING:

Von Willebrand Disease

VELORA Discover

Observational
prospective screening study of bleeding and treatment in VWD Type 1
(NCT06610201)

VELORA Pioneer

Phase 1
study of HMB-002 to prevent & reduce the frequency of bleeding in VWD Type 1
(NCT06754852)

Country	*Site*
United Kingdom	Richmond Pharmacology (London)

Next: First-in-human dose of HMB-002 in Q1-2025

Thank you